Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Acceleration of the world’s first autotaxin inhibitor for the treatment of pancreatic cancer (PDAC)

Project description

A breakthrough approach to pancreatic cancer treatment

Pancreatic cancer remains one of the deadliest cancers, with limited treatment options and a devastating impact on patients’ quality of life. Current therapies often fail to control the growth and spread of the disease. The complex tumour-stroma-immune (T-S-I) interface, which drives cancer progression and resistance to treatment, has remained an untapped area for effective interventions. As a result, there is an urgent need for innovative therapies. The EIC-funded CURE-PDAC project aims to advance iOnctura’s promising drug, IOA-289, a first-in-class autotaxin inhibitor. This novel treatment targets the T-S-I interface, offering a groundbreaking approach to combat pancreatic cancer. Through Phase I/II clinical trials, CURE-PDAC seeks to accelerate IOA-289’s development and attract further investment for its transformative potential.

Objective

iOnctura is a clinical stage biopharmaceutical company dedicated to delivering innovative cancer treatments to patents with unmet medical needs. iOnctura’s unique pipeline of drugs unlock mechanisms at the tumour-stroma-immune (T-S-I) interface, a multi cell-network that is responsible for driving tumour growth and survival as well as treatment resistance.
Pancreatic cancer is one of the most lethal cancers associated with devastating impact on the quality of life of patients; current treatments are largely ineffective and there is a need for game-changing therapies. IOA-289, is a first in class autotaxin (ATX) inhibitor that tackles cancer growth and spread by affecting core mechanisms at the T-S-I interface.
The EIC Accelerator funding for CURE-PDAC will allow iOnctura to accelerate the clinical development of IOA-289 as a treatment for pancreatic cancer through Phase I/II clinical trials, reach a major value inflection point and attract further financial investment into the company.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-EIC-2022-ACCELERATOR-01

See all projects funded under this call

Coordinator

IONCTURA BV
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 2 500 000,00
Address
BARBARA STROZZILAAN 201
1083 HN Amsterdam
Netherlands

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 5 906 503,00
My booklet 0 0